Internet Privacy Statement

Mesoblast is committed to protecting the privacy of visitors to its web site. This Internet Privacy Statement is provided to make you aware of how Mesoblast collects, uses and manages information of visitors to the website.

Mesoblast collects the following information regarding visitors to our web site: network identity of the computer system (IP address), domain name and information regarding what pages are accessed. This information is used for the purpose of capacity planning and research on usage patterns to further improve the site. Information volunteered by you, such as e-mail address, name and company details, is used for the express purpose for which it was disclosed. For example, Mesoblast may contact you to provide copies of announcements to the Australian Stock Exchange or e-Newsletters.

If you no longer wish to receive e-mails from Mesoblast, you should send an e-mail to info@mesoblast.com and write ‘unsubscribe’ in the subject line, so that we can remove you from our database.

Mesoblast only discloses your personal information to its employees and consultants who are bound to respect the privacy of this information. Otherwise, Mesoblast does not disclose your information to third parties or publish personal information collected through its website without consent. You can access any personal information which Mesoblast may hold about you by contacting its privacy officer through info@mesoblast.com

Cookies

Mesoblast’s website use cookies. Cookies are pieces of information that a website transfers to an individual’s computer for record-keeping purposes. The only personal information that a cookie can contain is information you personally supply.

Mesoblast recommends you accept cookies to take full advantage of the services its website provides. They allow us to customise information to improve user experience and for tracking user navigation.

However, if you are concerned about the use of cookies, you can set your browser to refuse cookies, or to warn you when cookies are used.

Links to other sites

This site contains links to other sites. Mesoblast is not responsible for the content of these websites nor the privacy of your personal information should you choose to access these websites.

Updating this Internet Privacy Statement

Mesoblast’s website will be continually improved and enhanced with new services, which may change the way we manage information. The content of this Internet Privacy Statement may be updated from time to time to reflect this, so we suggest that you return to this privacy statement on a regular basis and carefully read the information provided. This page was last updated on 14 January 2005.

 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine